{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:34:35Z","timestamp":1793064875534,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,2]],"date-time":"2027-10-02T00:00:00Z","timestamp":1822435200000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jss.2026.08.055","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:27:37Z","timestamp":1790976457000},"page":"481-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma"],"prefix":"10.1016","volume":"327","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-2641","authenticated-orcid":false,"given":"Orly N.","family":"Farber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Yacine","family":"Bennaceur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Karneris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-2121","authenticated-orcid":false,"given":"George","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2026.08.055_bib1","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in Melanoma: recent advances and future directions","volume":"15","author":"Knight","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jss.2026.08.055_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15656","article-title":"Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US","volume":"3","author":"Moyers","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jss.2026.08.055_bib3","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1245\/s10434-019-07599-y","article-title":"Survival outcomes of patients with clinical stage III melanoma in the era of novel systemic therapies","volume":"26","author":"Song","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2026.08.055_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/CJI.0000000000000264","article-title":"Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States","volume":"42","author":"Haque","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.jss.2026.08.055_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COC.0000000000001083","article-title":"Disparities in the receipt of systemic treatment in metastatic Melanoma","volume":"47","author":"Kakish","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jss.2026.08.055_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/1750743X.2025.2452836","article-title":"Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes","volume":"17","author":"Ali","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jss.2026.08.055_bib7","first-page":"2897","article-title":"Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective","volume":"38","author":"Al-Qurayshi","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jss.2026.08.055_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10903-023-01536-8","article-title":"Immunotherapy treatment disparities: a Texas cancer registry analysis of patients with cutaneous melanoma","volume":"26","author":"Ramirez","year":"2024","journal-title":"J Immigr Minor Health"},{"key":"10.1016\/j.jss.2026.08.055_bib9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaad.2020.08.097","article-title":"The ongoing racial disparities in melanoma: an analysis of the surveillance, epidemiology, and end results database (1975-2016)","volume":"84","author":"Qian","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jss.2026.08.055_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/COC.0000000000000074","article-title":"Hospital case volume is associated with improved survival for patients with metastatic Melanoma","volume":"39","author":"Huo","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jss.2026.08.055_bib11","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1200\/JCO.2018.36.15_suppl.9524","article-title":"Association between hospital volume and overall survival (OS) of stage 3 and 4 cutaneous malignant melanoma (MMel)","volume":"36","author":"Kommalapati","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2026.08.055_bib12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.6004\/jnccn.2019.7320","article-title":"Association between hospital volume, therapy types, and overall survival in stage III and IV cutaneous malignant melanoma","volume":"17","author":"Tella","year":"2019","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.jss.2026.08.055_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2018.10.026","article-title":"Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival","volume":"80","author":"Cheraghlou","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jss.2026.08.055_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50237","article-title":"Comparison of capture rates of the national cancer database across race and ethnicity","volume":"6","author":"Satpathy","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jss.2026.08.055_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jss.2026.08.055_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102104","article-title":"Racial and ethnic disparities in survival outcomes of metastatic renal cell carcinoma patients receiving immunotherapy","volume":"22","author":"Gupta","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jss.2026.08.055_bib17","article-title":"Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: a Texas study","volume":"12","author":"Olateju","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jss.2026.08.055_bib18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/jnci\/djad132","article-title":"Unequal racial distribution of immunotherapy for late-stage non-small cell lung cancer","volume":"115","author":"Chang","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jss.2026.08.055_bib19","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.32527","article-title":"Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States","volume":"76","author":"Ahn","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jss.2026.08.055_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/jamadermatol.2021.2215","article-title":"Melanoma and racial health disparities in black individuals-facts, fallacies, and fixes","volume":"157","author":"Marchetti","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jss.2026.08.055_bib21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamaoncol.2023.6025","article-title":"Immunotherapy initiation at the end of life in patients with metastatic cancer in the US","volume":"10","author":"Kerekes","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jss.2026.08.055_bib22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/cancers17030468","article-title":"Acral Melanoma in skin of color: current insights and future directions: a narrative review","volume":"17","author":"Nadelmann","year":"2025","journal-title":"Cancers"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480426005652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480426005652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:25:09Z","timestamp":1793064309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480426005652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"alternative-id":["S0022480426005652"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2026.08.055","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2026.08.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}